THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is G8807B956. A total of 4 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9 | -86.6% | 900 | -85.5% | 0.00% | – |
| Q1 2023 | $67 | -56.2% | 6,200 | -54.7% | 0.00% | – |
| Q4 2022 | $153 | -100.0% | 13,700 | -84.1% | 0.00% | -100.0% |
| Q3 2022 | $871,000 | +1483.6% | 85,900 | +1308.2% | 0.00% | – |
| Q2 2022 | $55,000 | -82.8% | 6,100 | -81.8% | 0.00% | – |
| Q1 2022 | $320,000 | +15900.0% | 33,500 | +16650.0% | 0.00% | – |
| Q4 2021 | $2,000 | -93.5% | 200 | -90.9% | 0.00% | – |
| Q3 2021 | $31,000 | 0.0% | 2,200 | 0.0% | 0.00% | – |
| Q2 2021 | $31,000 | -47.5% | 2,200 | +7486.2% | 0.00% | – |
| Q1 2021 | $59,000 | +5800.0% | 29 | +2800.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 1 | -50.0% | 0.00% | – |
| Q3 2020 | $2,000 | -80.0% | 2 | -60.0% | 0.00% | – |
| Q2 2020 | $10,000 | -56.5% | 5 | -44.4% | 0.00% | – |
| Q4 2019 | $23,000 | +666.7% | 9 | +800.0% | 0.00% | – |
| Q3 2018 | $3,000 | -25.0% | 1 | -91.7% | 0.00% | – |
| Q4 2017 | $4,000 | -76.5% | 12 | -65.7% | 0.00% | -100.0% |
| Q3 2017 | $17,000 | – | 35 | +1650.0% | 0.00% | – |
| Q1 2017 | $0 | -100.0% | 2 | -90.0% | 0.00% | – |
| Q4 2016 | $7,000 | +600.0% | 20 | +122.2% | 0.00% | – |
| Q1 2016 | $1,000 | – | 9 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIMPLEX TRADING, LLC | 85,900 | $871,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 20,700 | $210,000 | 0.00% |
| JANE STREET GROUP, LLC | 20,400 | $207,000 | 0.00% |